Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	6,529	4,882	7,694	5,661	5,774	2,598
Market Cap Growth	-0.20%	-36.54%	35.90%	-1.95%	122.22%	22.85%
Enterprise Value	7,567	6,046	8,836	5,796	5,802	2,579
PE Ratio	21.20	17.34	38.06	14.06	44.73	-35.97
PS Ratio	7.57	5.89	11.66	12.77	21.58	13.26
PB Ratio	36.72	58.26	45.31	28.74	38.22	28.31
P/FCF Ratio	15.41	13.08	29.44	19.00	106.87	-29.04
P/OCF Ratio	15.15	12.56	32.04	18.91	104.12	-30.42
EV/Sales Ratio	8.77	7.29	13.39	13.08	21.68	13.16
EV/EBITDA Ratio	15.27	13.38	28.01	22.38	37.93	-45.60
EV/EBIT Ratio	18.42	16.47	33.24	22.64	38.77	-42.54
EV/FCF Ratio	17.86	16.20	33.82	19.45	107.40	-28.83
Debt / Equity Ratio	8.44	17.89	8.87	4.45	2.63	4.39
Debt / EBITDA Ratio	3.03	3.32	4.77	3.38	2.60	-7.12
Debt / FCF Ratio	3.54	4.02	5.76	2.94	7.35	-4.50
Quick Ratio	5.01	5.07	4.54	7.11	1.11	5.62
Current Ratio	6.64	6.64	5.65	7.91	1.32	6.35
Asset Turnover	0.47	0.47	0.40	0.41	0.50	0.44
Interest Coverage	21.94	19.57	15.69	34.02	7.35	-5.21
Return on Equity (ROE)	192.70%	204.80%	98.60%	241.90%	124.80%	-33.70%
Return on Assets (ROA)	17.50%	15.80%	12.20%	37.60%	24.30%	-16.20%
Return on Capital (ROIC)	18.37%	17.24%	12.96%	41.64%	26.27%	-13.68%
Earnings Yield	4.88%	5.77%	2.63%	7.11%	2.24%	-2.78%
FCF Yield	6.49%	7.65%	3.40%	5.26%	0.94%	-3.44%
Buyback Yield / Dilution	6.54%	4.56%	4.22%	-3.77%	1.99%	-0.51%
Total Shareholder Return	6.54%	4.56%	4.22%	-3.77%	1.99%	-0.51%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).